Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | CDK2 | P24941 | 4/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.36 |
| ▸ | CDC7 | O00311 | 3/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.36 |
| ▸ | PRKACA | P17612 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.36 |
| ▸ | HIPK2 | Q9H2X6 | 2/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.35 |
| ▸ | CLK2 | P49760 | 4/20 | 0.35 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.35 |
| ▸ | CDK1 | P06493 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL980719 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL979417 | 0.80 | MAOB (0.43) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL981273 | 0.80 | PGR (0.42) | ALDH1A1HPGDRAB9ASMN1; SMN2ABL1 | |
| SCHEMBL980254 | 0.80 | PGR (0.46) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL984420 | 0.80 | HCRTR1 (0.45) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL979329 | 0.78 | ALDH1A1 (0.37) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL980474 | 0.78 | MAOB (0.58) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL979452 | 0.78 | PGR (0.41) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL17004388 | 0.78 | GRM5 (0.39) | ALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL981217 | 0.78 | CYP11B1 (0.37) | ROCK2ROCK1ALDH1A1HPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | claimed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | claimed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | claimed |
| EP-1917248-B1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| US-7875644-B2 | tyrosine kinase inhibitors, in particular Met kinase; antitumor agents;1-(Benzo-1,2,5-thiadiazol-5-ylmethylcarbonyl)-3-(2,4-dimethoxyphenyl)-4,5-dihydro-1H-pyrazole; leukemia, carcinomas | MERCK PATENT GMBH (DE) | 2011-01-25 | — | — | US | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2008-10-09 | — | — | US | disclosed |
| WO-2007019933-A1 | 1-ACYLDIHYDROPYRAZOL DERIVATIVES | MERCK PATENT GMBH (DE) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249095-A1 | 1-Acyldihydropyrazole Derivatives | MET, FLT3, ERBB3 | JAK2 11/4885MCHR1 1843/4885ROCK2 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.